GLSV news
01.02.2013 Global Life Science Ventures: 2012 Review 
more...
30.01.2012 Global Life Science Ventures: 2011 Review
more...
24.01.2011 Global Life Science Ventures: 2010 Review
more...
14.01.2010 Global Life Science Ventures: 2009 Review
more...
13.02.2009 Global Life Science Ventures: 2008 highlights
more...
22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award"
more...
14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008
more...
17.01.2008 GLSV leads investment in Action Pharma A/S
more...
06.12.2007 GLSV invests in Pelikan Technologies
more...
02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...
............................................................................................
Portfolio company news
08.12.2015 Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration more...
30.11.2015 Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration more...
19.11.2015 Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program more...
30.09.2015 Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team more...
15.09.2015 Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference more...
18.08.2015 Pieris Pharmaceuticals Appoints Louis A. Matis, M.D., as Chief Development Officer more...
28.07.2015 Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock more...
08.07.2015 Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics more...
06.07.2015 Pieris Pharmaceuticals Closes Public Offering of Common Stock more...
30.06.2015 Pieris Pharmaceuticals Prices Public Offering of Common Stock more...
10.06.2015 Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia more...
21.05.2015 Nabriva Therapeutics appoints Elyse Seltzer, MD, as Chief Medical Officer more...
19.05.2015 Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference more...
14.05.2015 Pieris Pharmaceuticals Appoints Immuno-Oncology Expert, Holbrook Kohrt, M.D., Ph.D., to Spearhead Immuno-Oncology Efforts and Initiates Research Collaboration with Leading Cancer Research Center more...
12.05.2015 Pieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive,
Jean-Pierre Bizzari, M.D., to its Board of Directors more...
07.04.2015 Nabriva Therapeutics announces financing of up to $120 million to advance clinical development of new class of antibiotic more...
30.03.2015 Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program more...
04.03.2015 Pieris to Present at Two Upcoming Conferences BIO-Europe Spring 2015 & the 27th Annual ROTH Conference more...
04.03.2015 Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference more...
10.02.2015 Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test more...
29.01.2015 Nabriva Therapeutics strengthens Board and Management Team more...
18.12.2014 Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million more...
11.12.2014 Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia more...
08.12.2014 Pieris Achieves GLP Tox Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more...
04.12.2014 Agendia’s MammaPrint and BluePrint Tests to be highlighted at San Antonio Breast Cancer Symposium more...
01.12.2014 Pieris Achieves Second Preclinical Milestone Payment in Sanofi Collaboration more...
12.11.2014 Pieris Appoints Michael Richman as Supervisory Board Member more...
09.10.2014 Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds more...
08.10.2014 Nabriva Therapeutics announces qualified infectious disease product and fast track status granted by the US FDA for lefamulin more...
02.10.2014 Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO more...
15.09.2014 Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide
to Pre-Surgical Treatment, Study Finds more...
08.09.2014 Nabriva Therapeutics presented data on lead pleuromutilin antibiotic lefamulin (BC-3781) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington DC more...
03.09.2014 Nabriva Therapeutics Appoints Dr Colin Broom As Chief Executive Officer more...
02.09.2014 Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment more...
04.08.2014 Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines more...
31.07.2014 Agendia Co-Founder and
CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer more...
16.07.2014 Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer more...
23.06.2014 Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more...
10.06.2014 Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting more...
09.06.2014 African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer more...
12.05.2014 Nabriva Therapeutics presents extended spectrum pleuromutilin antibiotics at the 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona more...
07.05.2014 Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports more...
24.04.2014 Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development more...
26.03.2014 Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests more...
11.03.2014 Agendia Co-Founder Awarded EU Prize for Women Innovators more...
11.03.2014 Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence more...
17.02.2014 Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome more...
10.02.2014 Pieris Achieves Preclinical Milestone Payment in Sanofi Collaboration more...
30.01.2014 Agendia’s MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference more...
27.01.2014 Nabriva Therapeutics Receives ZIT Grant for Extended Spectrum Pleuromutilin (ESP) Program more...
13.01.2014 Pieris Achieves Fourth Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics more...
10.01.2014 Santaris Pharma A/S announce agreement with GlaxoSmithKline (GSK) to develop RNA-targeted medicines more...
09.01.2014 Santaris A/S announces worldwide discovery alliance for RNA-targeted medicines with Roche more...
08.01.2014 Isarna Therapeutics and Santaris Pharma Announce License Agreement for the Development of Next Generation Oligonucleotides to Treat TGF-β-Mediated Diseases more...
08.01.2014 Santaris Pharma A/S Announces Appointment of J. Donald deBethizy as President and Chief Executive Officer more...
17.12.2013 Stelis Biopharma and Pieris Forge Alliance for Novel Anticalin® Therapeutics in Ophthalmology more...
25.11.2013 Pixium Vision raises €15 million led by Sofinnova Partners more...
12.11.2013 Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics more...
28.10.2013 Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc. more...
21.10.2013 Horizon Pharma announces Clinical Data on AYOS(R) (Prednisone) Delayed-Release Tablets to be presented at the American College of Rheumatology Annual Meeting more...
16.10.2013 Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics more...
13.09.2013 Nabriva Therapeutics Presented Data on Potency, Safety, Tolerability and Pharmacokinetics of Pleuromutilin Antibiotic BC-3781
more...
09 09.2013 Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
more...
27.08.2013 Santaris Pharma A/S Completes Enrollment in Phase 2 Clinical Trial of Miravirsen In Null Responders to Pegylated Interferon and Ribavirin for the Treatment of the Hepatitis C Virus more...
27.08.2013 Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
more...
23.08.2013 Shire and Santaris extend their strategic alliance to discover and develop LNA-drugs in the rare genetic disease field
more...
08.07.2013 RaNA Therapeutics, Inc. and Santaris Pharma A/S announce agreement to develop RNA-targeted medicines that selectively activate protein expression
more...
03.06.2013 Agendia Appoints Peter W. Schineller as Chief Commercial Officer
more...
31.05.2013 Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
more...
29.05.2013 Horizon Pharma Announces Receipt of Fifth U.S. Patent Allowance for DUEXIS(R)
more...
23.05.2013 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
more...
